Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/17/2010

an overall survival benefit.  The study will enroll about 800 patients worldwide.  

While we already showed a 33% improvement in overall survival in Phase II, we only need 10% in the Phase III study to meet our primary endpoint. We have added multiple years to the development process of Multikine in order to build a Multikine dedicated manufacturing facility near Baltimore.  This was done at the advice of the regulatory agencies and as an additional step of risk mitigation since the use of a contract manufacturer adds a great deal of risk in maintaining quality control.  We have taken every conceivable risk mitigation step to increase the probability of a favorable outcome for this breakthrough product.

On the other hand, recognizing that every drug development carries risk, we have attempted to set the study up to become a huge financial success for the shareholders.  Assuming we are right, Multikine will become the first treatment to be used in the treatment of nearly all newly diagnosed head and neck cancer patients (about 650,000 patients worldwide).  It will become part of the new standard of care.  That means that doctors will be advised to use Multikine as the first treatment for head and neck cancer patients.  Insurance companies and governments should reimburse the use of Multikine because it will be cost effective and because they pay for the current standard of care treatments, surgery, radiation and chemotherapy.  This would translate into billions of dollars in sales while at the same time helping to save lives.  Usually such successes are shared with a big pharmaceutical partner and the upside for the small company's shareholders is limited.  In the case of CEL-SCI, shareholders still control most of the upside as CEL-SCI still owns all of the major marketing rights.  Very few companies find themselves in this advantageous position a
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 The National Association of Managed ... released the NAMCP Medical Technologies Dossier Template © ... © , which provide medical directors and manufacturers ... devices or diagnostics that accounts for evidence-based development ... technology types (instead of having to attempt to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
Breaking Medicine Technology:NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... Mass., Oct. 26 DUSA Pharmaceuticals, Inc.® (Nasdaq: ... dermatology announced today that it has been named to ... consecutive year, Deloitte recognized DUSA as one of the ... and clean technology companies in North America.  Rankings are ...
... Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop... -- INGELHEIM, Germany and ROCKVILLE, Md., Oct. 26 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 3Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 4Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 5Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 6Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 7Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 8Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 9Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 10
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, ... first objective scientific way to diagnose major depression in adults, ... of nine genetic indicators (known as "RNA markers") in the ... to cognitive behavioral therapy, one of the most common and ... worked, Northwestern University researchers report. Depression affects nearly 7 ...
(Date:9/16/2014)... Tara Haelle HealthDay Reporter ... 14.5 million U.S. cancer survivors are alive today, compared ... for Cancer Research reported Tuesday. These individuals amount ... 380,000 survivors of childhood cancer, according to the association,s ... identification, research and treatment of cancer and details some ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Thousands ... against C.R. Bard, Inc. continue to move forward ... District Court, Southern District of West Virginia, Bernstein ... September 15, 2014, the Court has determined that ... the proceeding. The Order indicates that the first ...
(Date:9/16/2014)... NC (PRWEB) September 16, 2014 Danny ... on a Fall workshop tour with events throughout the ... the natural running movement and has taught a full ... is now offering ChiWalk-Run and ChiWalking tracks at his ... enjoy the benefits of the Chi techniques. , Workshop ...
(Date:9/16/2014)... Sept. 16, 2014 (HealthDay News) -- One in ... his spouse or partner, a new survey shows. ... of Michigan revealed that such violence is more ... shoving, grabbing, throwing objects, slapping and hitting, kicking, ... a weapon, the researchers said. Although abuse ...
Breaking Medicine News(10 mins):Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 2Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 3Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2
... breast cancer detection today is X-ray mammography, which takes ... However, there are several disadvantages to using X-rays for ... of radiation and the high costs, which limit their ... In addition, depending on the age of the patient ...
... ... Founded by a Kaiser Permanente Oncologist, the Organization Counts Sarah Obama, the U.S. ... is a Departure from Traditional Grant-making. , ... (PRWEB) July 7, 2010 -- The Tiba Foundation ...
... ... endocrinologists as the top company overall in a recent SDI study. Novo Nordisk increased ... ... study, Novo Nordisk was ranked by endocrinologists as the top company overall. The company ...
... Bling My Sling LLC is ... wide array of arm slings and healing products that are designed for helping bone injuries to ... , ... -- Bling My Sling LLC, a fashionable arm sling manufacturer, today announce the opening of their ...
... ... newsletter, Allergy Consumer Report. The series highlights the doctors who treat patients with ... relief products. , ... (PRWEB) July 7, 2010 -- This month,s issue of the Allergy Consumer Report ...
... ... tour intensifies as Hamner,s single, "The View" hits radio on July 6th. ... Atlanta, GA (PRWEB) ... Hamner, is traveling the South and Southeast this summer for Ryan Hamner Presents: “Hear ...
Cached Medicine News:Health News:Mathematical models for breast cancer detection with microwave tomography are cheaper and less risky 2Health News:State of the Art Hospital for Rural Kenya Announced by California Foundation 2Health News:State of the Art Hospital for Rural Kenya Announced by California Foundation 3Health News:SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study 2Health News:Bling My Sling LL Announces Website Launch - A fashionable arm sling manufacturer, announce the opening of their new website bling-my-sling.com 2Health News:AchooAllergy.com Adds Allergist Interviews to Monthly Allergy Consumer Report Newsletter 2Health News:AchooAllergy.com Adds Allergist Interviews to Monthly Allergy Consumer Report Newsletter 3Health News:Ryan Hamner's Free Hear The Heart Tour Sweeping The South Four-Time Cancer Survivor, Sings Hope To Others 2
... 265 is a highly accurate portable, waterproof system ... measurements. Temperature compensated pH results can be obtained ... a 3-in-1 electrode. • This GLP/GMP compliant system ... printer or a computer. Up to 100 data ...
... a highly accurate portable system for pH, mV ... pH results can be obtained when used with ... • This GLP/GMP compliant system includes an RS-232 ... computer. Up to 100 data sets can be ...
... Over-sized compressor. Triple pane thermal glass. ... System No plumbing required. Equipped with a ... on Parts & Labor and an Additional 4 ... as a chromatography unit which includes two access ...
... equipped, waterproof system for pH, mV (ORP), relative ... pH results can be obtained when used with ... Up to five custom buffers are supported. • ... to connect to a printer or a computer. ...
Medicine Products: